Combinations ; See Below
| Oxymetazoline Brands |
|---|
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Nasivion | Cipla Ltd. | Surgipharm Ltd | 0.025% | 10ml | Nasal spray/drops | KES 120.00 | |
| Nasivion | Cipla Ltd. | Surgipharm Ltd | 0.05% | 10ml | Nasal spray/drops | KES 130.00 | |
| Oxylin | Allergan International Ltd. | Radiance Pharmaceuticals Limited | 0.025% | 15ml | eye drops | per ml | KES 410.00 |
| Utabon | J. Uriach & CIA | Globe Pharmacy Ltd., | 0.025% | 15ml | Nasal spray/drops | KES 178.20 | |
| Utabon | J. Uriach & CIA | Globe Pharmacy Ltd., | 0.05% | 15ml | Nasal spray/drops | KES 201.30 |
Oxymetazoline More info
Use
Adjunctive therapy for nasal congestion, associated with acute or chronic rhinitis, the common cold, sinusitis, hay fever, or other allergies
Adverse Reactions Significant
Frequency not defined.
Respiratory: Dryness of the nasal mucosa, nasal irritation (temporary), rebound congestion (chronic use), sneezing
Contraindications
Hypersensitivity to oxymetazoline or any component of the formulation
Warnings/Precautions
Concerns related to adverse effects:
• Rebound nasal congestion: May occur with extended use.
Disease-related concerns:
• Cardiovascular disease: Use with caution in patients with hypertension, heart failure, or coronary artery disease.
• Diabetes: Use with caution in patients with diabetes mellitus.
• Hyperthyroidism: Use with caution in patients with hyperthyroidism.
• Prostatic hyperplasia: Use with caution in patients with benign prostatic hyperplasia.
Drug Interactions
(For additional information: Launch Lexi-Interact™ Drug Interactions Program )
Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics. Risk C: Monitor therapy
Cannabinoids: May enhance the tachycardic effect of Sympathomimetics. Risk C: Monitor therapy
Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. Risk X: Avoid combination
MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. Risk X: Avoid combination
Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Risk C: Monitor therapy
Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists. Risk D: Consider therapy modification
Pregnancy Implications
Adverse fetal or neonatal effects have not been observed following normal maternal doses of oxymetazoline during the third trimester of pregnancy. Adverse events have been noted in case reports following large doses or extended use. Decongestants are not the preferred agents for the treatment of rhinitis during pregnancy. Short-term (<3 days) use of intranasal oxymetazoline may be beneficial to some patients although its safety during pregnancy has not been studied